Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Name:
Sunitinib in pancreatic neuroe ...
Size:
312.4Kb
Format:
PDF
Description:
Main article
Authors
Faivre, SNiccoli, P
Castellano, D
Valle, Juan W
Hammel, P
Raoul, J
Vinik, A
Van Cutsem, E
Bang, Y
Lee, S
Borbath, I
Lombard-Bohas, C
Metrakos, P
Smith, D
Chen, J
Ruszniewski, P
Seitz, J
Patyna, S
Lu, D
Ishak, K
Raymond, E
Affiliation
Medical Oncology and Gastroenterology Department, Service Inter-Hospitalier de Cancerologie, Hopital Beaujon, Clichy, FranceIssue Date
2016-11-10
Metadata
Show full item recordAbstract
In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.Citation
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. 2016, Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdw561PubMed ID
27836885Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw561
Scopus Count
Collections
Related articles
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
- Authors: Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P
- Issue date: 2011 Feb 10
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
- Authors: Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E
- Issue date: 2016 Dec
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
- Authors: Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE
- Issue date: 2015 May 20
- FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
- Authors: Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R, Pazdur R
- Issue date: 2012
- Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
- Authors: Fazio N, Kulke M, Rosbrook B, Fernandez K, Raymond E
- Issue date: 2021 Jan